MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC
The MYC oncogene is dysregulated in most human cancers and hence is an attractive target for cancer therapy. We and others have shown experimentally in conditional transgenic mouse models that suppression of the MYC oncogene is sufficient to induce rapid and sustained tumor regression, a phenomenon...
Main Authors: | Renumathy Dhanasekaran, Jangho Park, Alekesey Yevtodiyenko, David I. Bellovin, Stacey J. Adam, Anand Rajan KD, Meital Gabay, Hanan Fernando, Julia Arzeno, Vinodhini Arjunan, Sergei Gryanzov, Dean W. Felsher |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253120301979 |
Similar Items
-
MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity
by: Renumathy Dhanasekaran, et al.
Published: (2020-01-01) -
Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC
by: Akira Asai, et al.
Published: (2017-04-01) -
NanoSIMS Imaging Reveals the Impact of Ligand-ASO Conjugate Stability on ASO Subcellular Distribution
by: Emma Kay, et al.
Published: (2022-02-01) -
PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter
by: Meng Zhu, et al.
Published: (2023-03-01) -
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
by: Rosie Z Yu, et al.
Published: (2016-01-01)